BIOVITRUM Aktie

2,43 EUR -1,0993%

Zu Ihrem Onlinebroker

kaufen verkaufen

BIOVITRUM Aktienkurs : 09:04 ( 15 Min. verzögert)
2,43 € Letzter Kurs	-1,10% Veränderung	2,46 € Vortag	2,45 € Eröffnungskurs

Realtime:

2,43

-1,10%

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
2,45 - 2,43 Tag	2,79 - 1,24 52 Wochen	0 Tag	44 Ø 52 Wochen	2,47 3.244 Stücke	2,52 3.180 Stücke

BIOVITRUM Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

17.05.

Gentium Reports First Quarter Financial Results

... Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) for the distribution of Defibrotide in countries in Central and Eastern Europe, and with Swedish Orphan Biovitrum ...
17.05.

Gentium Reports First Quarter Financial Results

... Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) for the distribution of Defibrotide in countries in Central and Eastern Europe, and with Swedish Orphan Biovitrum ...

17.05.

Gentium Reports First Quarter Financial Results

... Inc. (NYSE:VRX) (TOR:CA:VRX) for the distribution of Defibrotide in countries in Central and Eastern Europe, and with Swedish Orphan Biovitrum AB (stockholm:SOBI) for the distribution of Defibrotide in the Baltics and Nordics, together with our ...
17.05.

Gentium Reports First Quarter Financial Results

... Inc. (NYSE:VRX) (TOR:CA:VRX) for the distribution of Defibrotide in countries in Central and Eastern Europe, and with Swedish Orphan Biovitrum AB (stockholm:SOBI) for the distribution of Defibrotide in the Baltics and Nordics, together with our ...
16.05.

Santarus' CEO Presents at Bank of America Merrill Lynch 2012 Health Care ...

The product is already on the market in Europe under the trademark Ruconest sold by Swedish Orphan Biovitrum. The data was quite compelling in terms of time to begin the relief of symptoms in both of the clinical...